期刊文献+

氯吡格雷单次和多次给药在大鼠体内的药动学特征 被引量:3

Pharmacokinetic characteristics of clopidogrel in rats after single dose and multiple doses of oral administration
原文传递
导出
摘要 目的建立并确证氯吡格雷羧酸代谢物SR26334血浆药物浓度的HPLC检测法,研究氯吡格雷单次和多次大剂量给药后在大鼠体内的药动学特征。方法 12只SD大鼠随机分成2组(单次给药组和多次给药组),单次和多次灌胃给予氯吡格雷30 mg·kg^(-1),多次给药为每天1次,共7 d。采用HPLC法测定给药后不同时间点血浆中SR26334浓度,用DAS 3.0处理经时血药浓度数据,计算主要药动学参数。结果单次给药和多次给药后SR26334血药浓度均于给药后约1 h达峰,ρ_(max)分别为(35.57±10.25)mg·L^(-1)和(54.28±10.39)mg·L^(-1);两者t_(1/2x)相近,分别为(6.88±1.54)h和(6.54±1.04)h;AUC_(0→24h)分别为(304.63±63.07)mg·h·L^(-1)和(543.81±43.27)mg·h·L^(-1);AUC_(0→∞)分别为(334.00±66.24)mg·h·L^(-1)和(594.91±46.84)mg·h·L^(-1);V_z/F分别为(0.92±0.23)L·kg^(-1)和(0.48±0.07)L·kg^(-1);CLz/F分别为(0.09±0.02)L·h^(-1)·kg^(-1)和(0.05±0.00)L·h^(-1).kg^(-1)。结论氯吡格雷单次与多次给药后的主要药动学参数AUC_(0→24h)、AUC_(0→∞)、V_z/F、CLz/F和ρ_(max)差异具有统计学意义(P<0.01,P<0.05),说明多次大剂量给药时其代谢物SR26334在体内有蓄积。 AIM To develop a HPLC method for the determination of carboxylic acid metabolite of clopidogrel in rat plasma, and study its pharmacokinetic profiles after single and multiple large dosage of oral administration. METH- ODS Twelve SD rats were divided into 2 groups which were orally administrated with single dose( 30 mg kg-1. d-l) and multiple doses ( 30 mg kg-1 d-1, one dose per day, 7 continuous days)of clopidogrel, respectively. SR26334 concentrations in plasma were determined by HPLC method. The pharmacokinetie parameters of SR26334 were obtained with statistical analysis by DAS 3.0 software. RESULTS The main pharmaeokinetie parameters of single dose group and muhiple doses group were as follows: t1/2z were (6.88 ±1.54) h and (6.54 ± 1.04) h, tmax were (1.10±0.55) h and (1.17±0.41)h, Pm,xwere (35.57±10.25) mg L-1 and (54.28±10.39) mg L-1, AUC0-24h were (304.63± 63.07) mg h L-1 and (543.81 ±43.27) mg h L-1,AUC0-∞ were (334.00 ± 66.24) mg'h'L-1 and (594.91 ± 46.84) mg h L-1,VZ/F were (0.92±0.23)L kg-1 and (0.48±0.07) L kg-1, CLz/F were (0.09±0.02) L h-1 kg- 1 and (0.05 ± 0.00) L h- 1 kg- 1 , respectively. CONCLUSION The differences of the main pharmacoki- netic parameters of AUC0-24h, AUC0-∞ , Vz/F, CLz/F and Pmax between 2 groups are significant( P 〈 0.01, P 〈 0.05). After multiple large dosage of clopidogrel, there are drag accumulation in vivo.
出处 《中国临床药学杂志》 CAS 2013年第2期77-81,共5页 Chinese Journal of Clinical Pharmacy
基金 温州市科技计划项目(编号Y20100262)
关键词 氯吡格雷 SR26334 药动学 高效液相色谱法 clopidogrel SR26334 pharmacokinetics HPLC
  • 相关文献

参考文献8

  • 1Cavusoglu E, Chenget J, Bhatt R, et al. Clopidogrel in the management of ischemie heart diseasel[J]. Heart Dis,2003,5(2) :144.
  • 2倪唤春,范维琥.抗血小板新药——氯吡格雷[J].中国新药杂志,2001,10(12):888-891. 被引量:44
  • 3Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus stan- dard-dose clopidogrel and high-dose remus low-dose aspirin in individu- als undergoing percutaneous coronary intervention for acute coronary syn- dromes ( CURRENT-OASIS 7 )- a randomised factorial trial [ J ]. Lancet, 2010,376(9748) : 1233.
  • 4Singh SS, Sharma K, Barot D, et al. Estimation of carboxylic acid mctabolite of c]opidogrcl in Wistar rat plasma by HPLC and its applica- tion to a pharmacokinetic study[J]. J Chromato@" B Analyt Technol Biomcd Life Sci, 2005,821(2):173.
  • 5Souri E, Jalalizadeh H, Kebriaee-Zadeh A, et al. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study [ J].Biomed Chromatogr, 2006,20 (12) : 1309.
  • 6樊宏伟,邹建军,林松,胡云芳,肖大伟.LC-MS/MS法同时测定人血浆中氯吡格雷及其羧酸代谢物的浓度[J].中国新药与临床杂志,2008,27(11):811-815. 被引量:22
  • 7Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of clopi-dogrel metabolite (SR26334) in human plasma by LC-MS[J]. J Pharm Biomed Anal,2006,41(2) :533.
  • 8王明亮,朱毅,甘洁民.急性冠脉综合征患者中氯吡格雷抵抗的发生率及影响因素[J].中国临床药学杂志,2010,19(3):142-144. 被引量:6

二级参考文献22

  • 1罗心平,施海明,倪唤春,朱军,王彩萍,李剑,范维琥.负荷剂量的氯吡格雷在38例急性心肌梗死直接支架术中的应用[J].中国新药与临床杂志,2004,23(10):667-670. 被引量:8
  • 2CAVUSOGLU E, CHENG J, BHATT R, et al. Clopidogrel in the management of ischemic heart disease[J]. Heart Dis, 2003, 5 (2) : 144-152.
  • 3FURMAN MI, KRUEGER LA, LINDEN MD, et al. GPⅡb-Ⅲa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention[J]. J Thromb Haemost, 2005, 3(2): 312-320.
  • 4SINGH SS, SHARMA K, BAROT D, et al. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 821 (2): 173-180.
  • 5LAINESSE A, OZALP Y, WONG H, et al. Bioequivalence study of clopidogrel bisulfate film-coated tablets [J]. Arzneimittelforschung, 2004, 54(9A): 600-604.
  • 6ROBINSON A, HILLIS J, NEAL C, et al. The validation of a bioanalytical method for the determination of clopidogrel in human plasma [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 848 (2): 344-354.
  • 7SINGH SS, SHARMA K, BAROT D, et al. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 821 (2) : 173-180.
  • 8KSYCINSKA H, RUDZLI P, BUKOWSKA-KILISZEK M. Determination of clopidogrel metabolite (SR26334)in human plasma by LC-MS[J]. J Pharm Biomed Anal, 2006, 41 (2): 533-539.
  • 9Gurbel PA, Bliden KP, Hiatt BI, et al. Clopidogrel for coronary stenting: response variability drug resistance and the effect of pretreatment platelet reactivity[J]. Circulation, 2003,107(23) :2908.
  • 10CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events[J]. Lancet, 1996, 348(9068) : 1329.

共引文献65

同被引文献85

引证文献3

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部